Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

NCT01664637 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

120

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient efficacy in planned interim futility analysis

Conditions

Diabetic Gastroparesis

Interventions

DRUG: 10 mg TZP-102
DRUG: Placebo

Sponsor

Tranzyme, Inc.